Kezar (KZR) SVP tenders shares as Aurinia merger cancels stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kezar Life Sciences SVP and Corporate Controller Chiang Pichi Luo reported tendering and canceling equity awards in connection with Kezar’s acquisition by Aurinia Pharma U.S., Inc. Luo disposed of 2,711 shares of common stock on May 11, 2026 pursuant to a tender offer at $6.955 per share in cash plus one non-tradable contingent value right (CVR) per share, as described in the merger terms.
On the same date, multiple employee stock options with exercise prices ranging from $6.30 to $22.80 per share were disposed of to the issuer and canceled at the merger effective time. Under the merger agreement, out-of-the-money options received no consideration, while in-the-money options were converted into cash and CVRs based on a stated formula. Following these transactions, this filing shows no remaining Kezar common shares or reportable options held by Luo.
Positive
- None.
Negative
- None.
Insights
Routine clean-up of equity positions from Kezar’s sale to Aurinia; no open‑market trading signal.
The transactions reflect how Kezar equity held by SVP, Corporate Controller Chiang Pichi Luo was treated in the change of control. Common shares were tendered for $6.955 per share plus one non‑tradable CVR, consistent with the merger consideration available to all tendering stockholders.
All reported employee stock options were canceled at the May 11, 2026 effective time. Footnotes state that options with exercise prices at or above the cash amount lapsed with no payment, while lower‑priced options converted into cash plus CVRs under a formula. With total_shares_following_transaction and derivativeSummary both at zero, this filing shows no remaining Kezar equity for this insider after the merger close.
The pattern is typical for a completed acquisition and does not involve discretionary buying or selling in the market. Any value realized stems from the agreed merger terms rather than timing decisions, so the informational content for future performance assessments is limited.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
Chiang Pichi Luo
Role
SVP, Corporate Controller
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 12,500 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 17,500 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 7,500 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 1,199 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 2,052 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 599 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 2,401 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 2,499 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 2,899 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 2,899 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 4,999 | $0.00 | -- |
| Disposition | Employee Stock Option (right to buy) | 7,999 | $0.00 | -- |
| U | Common Stock | 2,711 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time"). Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option. Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Key Figures
Common shares tendered: 2,711 shares
Tender offer cash price: $6.955 per share
Option tranche at $22.80: 7,999 options at $22.80
+5 more
8 metrics
Common shares tendered
2,711 shares
Disposed in tender offer on May 11, 2026
Tender offer cash price
$6.955 per share
Cash consideration per Kezar common share
Option tranche at $22.80
7,999 options at $22.80
Employee stock options disposed to issuer
Option tranche at $6.30
7,500 options at $6.30
Employee stock options canceled at merger
Option tranche at $6.58
17,500 options at $6.58
Employee stock options canceled at merger
Option tranche at $9.30
10,000 options at $9.30
Employee stock options disposed to issuer
Dispose transactions
14 transactions
All coded as dispositions in transactionSummary
Post-transaction holdings
0 shares/options
Total shares and derivative positions after transactions
Key Terms
tender offer, Cash Consideration, contingent value right, Agreement and Plan of Merger, +2 more
6 terms
tender offer financial
"Purchaser completed a tender offer for shares of the Issuer's Common Stock."
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
Cash Consideration financial
"In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash ... (the "Cash Consideration")."
Cash consideration is the actual money paid to buy a company, asset, or stake rather than payment in shares or other forms. For investors it matters because cash payments deliver immediate, certain value and affect the buyer’s and seller’s cash reserves and balance sheets—like selling a car for cash versus taking a trade-in, one side gets instant spending power while the other changes its liquidity and risk profile.
contingent value right financial
"plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash."
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
Agreement and Plan of Merger financial
"In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Out-of-the-Money Option financial
"each option ... that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option")."
An out-of-the-money option is a contract to buy or sell a stock that would not be profitable if exercised right now because the agreed price is on the wrong side of the current market price (for a call, the strike is higher than the market; for a put, the strike is lower). Investors care because these options cost less and act like inexpensive bets: they can offer big percentage gains if the stock moves enough, but are more likely to expire worthless, making them useful for speculative bets or low-cost hedges — like buying a lottery-style coupon that only pays off if the price crosses a specific line.
In-the-Money Option financial
"each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option")."
FAQ
What did Kezar Life Sciences (KZR) executive Chiang Pichi Luo report in this Form 4?
The Form 4 shows Chiang Pichi Luo tendered 2,711 Kezar common shares into Aurinia’s cash-and-CVR offer and had all reported employee stock options canceled or cashed out under the merger agreement, leaving no Kezar equity holdings reported after the transaction.
What happened to Kezar (KZR) employee stock options held by Chiang Pichi Luo in the merger?
Each reported employee stock option was automatically canceled at the merger effective time. Options with exercise prices at or above the cash amount received no payment, while options priced below the cash amount turned into cash plus CVRs, following formulas in the merger agreement.
Does this Kezar (KZR) Form 4 show any open-market buying or selling by the executive?
No. The filing reflects a tender offer disposition of common shares and issuer-directed cancellations or cashouts of employee stock options tied to the merger. It does not show any open-market purchases or sales initiated by the executive independently of the acquisition.
What consideration structure did Kezar (KZR) stockholders receive in the Aurinia tender offer?
Tendering stockholders received $6.955 per Kezar common share in cash, without interest and less tax withholding, plus one non-tradable contingent value right (CVR) per share. CVRs entitle holders to potential future cash payments if specified milestones outlined in the CVR agreement are achieved.